BRCA2 and breast carcinoma: Notably, this appeared to be driven largely by an 80% reduction in breast cancer related deaths in BRCA1 carriers, whereas there was no statistically significant effect of MRI on reducing mortality in those with BRCA2 pathogenic variants.